Advertisement

Applications in Head and Neck Cancer

  • Deepak Khuntia
  • Anne M. Traynor
  • Paul M. Harari
  • Jean Bourhis
Part of the Medical Radiology book series (MEDRAD)

Keywords

Clin Oncol Radiat Oncol Biol Phys Keratinocyte Growth Factor Advanced Head Concurrent Chemoradiation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adelstein DJ, Li Y, Adams GL et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98PubMedCrossRefGoogle Scholar
  2. Al-Sarraf M, LeBlanc M, Giri PG et al (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16:1310–1317PubMedGoogle Scholar
  3. American Cancer Society (2005) Cancer Facts and Figures 2005, available online under www.cancer.org/docroot/STT/stt_0.aspGoogle Scholar
  4. Andres L de, Brunet J, Lopez-Pousa A et al (1995) Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 13:1493–1500PubMedGoogle Scholar
  5. Antonadou D, Pepelassi M, Synodinou M et al (2002) Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 52:739–747PubMedCrossRefGoogle Scholar
  6. Bachaud JM, Cohen-Jonathan E, Alzieu C et al (1996) Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 36:999–1004PubMedCrossRefGoogle Scholar
  7. Bernier J, Domenge C, Ozsahin M et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945–1952PubMedCrossRefGoogle Scholar
  8. Bernier J, Cooper JS, Pajak TF et al (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 27:843–850PubMedCrossRefGoogle Scholar
  9. Bourhis J, Amand C, Pignon JP (2004) Update of MACH-NC (meta-analysis of chemotherapy in head and neck cancer) database focused on concomitant chemoradiotherapy (Abstract). J Clin Oncol 22:489sGoogle Scholar
  10. Brizel DM, Albers ME, Fisher SR et al (1998) Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798–1804PubMedCrossRefGoogle Scholar
  11. Brizel DM, Wasserman TH, Henke M et al (2000) Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339–3345PubMedGoogle Scholar
  12. Buntzel J, Kuttner K, Frohlich D et al (1998) Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 9:505–509PubMedCrossRefGoogle Scholar
  13. Buntzel J, Glatzel M, Kuttner K et al (2002) Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Semin Radiat Oncol 12:4–13PubMedCrossRefGoogle Scholar
  14. Calais G, Alfonsi M, Bardet E et al (1999) Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91:2081–2086PubMedCrossRefGoogle Scholar
  15. Calais G, Alfonsi M, Bardet E et al (2000) Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy. Bull Cancer 87 (Spec no.):48–53PubMedGoogle Scholar
  16. Chan AT, Teo PM, Leung TW et al (1995) A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 33:569–577PubMedCrossRefGoogle Scholar
  17. Cmelak AJ, Li S, Goldwasser M et al (2005) A phase II trial of chemoradiation (CR) for organ preservation in respectable stage III or IV squamous cell carcinomas of the larynx (L) or oropharynx (OP): a trial of the Eastern Cooperative Oncology Group (E2399). Abstract 5509, Proc Am Soc Clin Oncol, pp 5509Google Scholar
  18. Colevas AD, Norris CM, Tishler RB et al (1999) Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 17:3503–3511PubMedGoogle Scholar
  19. Cooper JS, Pajak TF, Forastiere AA et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937–1944PubMedCrossRefGoogle Scholar
  20. De Andres L, Brunet J, Lopez-Pousa A et al. (1995) Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 13:1493–1500PubMedGoogle Scholar
  21. Denis F, Garaud P, Bardet E et al (2004) Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22:69–76PubMedCrossRefGoogle Scholar
  22. Department of Veterans Affairs Laryngeal Cancer Study Group (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324:1685–1690CrossRefGoogle Scholar
  23. Dorr W, Reichel S, Spekl K (2005) Effects of keratinocyte growth factor (palifermin) administration protocols on oral mucositis (mouse) induced by fractionated irradiation. Radiother Oncol 75:99–105PubMedCrossRefGoogle Scholar
  24. El-Sayed S, Nelson N (1996) Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 14:838–847PubMedGoogle Scholar
  25. Fonseca E, Grau JJ, Sastre J et al (2005) Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study. Eur J Cancer 41:1254–1260PubMedCrossRefGoogle Scholar
  26. Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098PubMedCrossRefGoogle Scholar
  27. Garden AS, Harris J, Vokes EE et al (2004) Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 22:2856–2864PubMedCrossRefGoogle Scholar
  28. Gillison ML, Koch WM, Capone RB et al (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709–720PubMedCrossRefGoogle Scholar
  29. Gosselin TK, Raj KA, Clough RW et al (2005) Amifostine for Xerostomia: Normal tissue protection at what cost? Abstract 212, Proc Am Soc Ther Rad Oncol, Elsevier, pp S128Google Scholar
  30. Haddad RI, Tishler RB, Wirth L et al (2005) Rate of complete pathological responses (pCR) to docetaxel/cisplatin/5-fluorouracil (TPF) induction chemotherapy in patients with newly diagnosed, locally advanced squamous cell carcinoma of the head and neck (SCCHN). Abstract 5511, Proc Am Soc Clin OncolGoogle Scholar
  31. Hitt R, Lopez-Pousa A, Rodriguez M et al (2003) Phase III study comparing cisplatin (P) and 5-fluoruracil (F) versus P, F and paclitaxel (T) as induction therapy in locally advanced head and neck cancer (LAHNC). Abstract 1997, Proc Am Soc Clin OncolGoogle Scholar
  32. Hitt R, Grau J, Lopez-Pousa A et al (2005) Phase II/III trial of induction chemotherapy(ICT) with cisplatin/5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) followed by chemoradiotherapy (CRT) vs CRT for unresectable locally advanced head and neck cancer (LAHNC). Abstract 5578, Proc Am Soc Clin OncolGoogle Scholar
  33. Holsti LR, Mantyla M (1988) Split-course versus continuous radiotherapy. Analysis of a randomized trial from 1964 to 1967. Acta Oncol 27:153–161PubMedGoogle Scholar
  34. Johnson JT, Ferretti GA, Nethery WJ et al (1993) Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 329:390–395PubMedCrossRefGoogle Scholar
  35. Katori H, Tsukuda M, Ishitoya J et al (2005) Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation versus concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol, pp 5580Google Scholar
  36. Kish JA, Ensley J, Crissman J et al (1985) The role of induction chemotherapy in advanced head and neck cancer: the Wayne State University experience. Prog Clin Biol Res 201:177–189PubMedGoogle Scholar
  37. Kwong DL, Sham JS, Au GK (2003) Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. Proc Am Soc Clin Oncol 22:495Google Scholar
  38. Lee AW, Lau WH, Tung SY et al (2004) Prospective randomized study on therapeutic gain achieved by addition of chemotherapy for T1-4N2-3M0 nasopharyngeal carcinoma (NPC). Abstract 5506. Proc Am Soc Clin Oncol 22 No 14S:489sGoogle Scholar
  39. Lefebvre JL, Chevalier D, Luboinski B et al (1996) Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:890–899PubMedGoogle Scholar
  40. Munro AJ (1995) An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 71:83–91PubMedGoogle Scholar
  41. Pignon JP, Bourhis J, Domenge C et al (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Metaanalysis of chemotherapy on head and neck cancer. Lancet 355:949–955PubMedGoogle Scholar
  42. Posner MR (2001) Docetaxel in squamous cell cancer of the head and neck. Anticancer Drugs 12(Suppl 1):S21–S24PubMedGoogle Scholar
  43. Posner MR, Glisson B, Frenette G et al (2001) Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 19:1096–1104PubMedGoogle Scholar
  44. Psyrri A, Kwong M, DiStasio S et al (2004) Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. J Clin Oncol 22:3061–3069PubMedCrossRefGoogle Scholar
  45. Rischin D, Peters L, Fisher R et al (2005) Tirapazamine, cisplatin and radiation versus fluorouracil, cisplatin and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23:79–87PubMedCrossRefGoogle Scholar
  46. Rossi A, Molinari R, Boracchi P et al (1988) Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol 6:1401–1410PubMedGoogle Scholar
  47. Shin DM, Glisson BS, Khuri FR et al (2002) Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 95:322–330PubMedCrossRefGoogle Scholar
  48. Vermorken JB, Remenar E, van Herpen C et al (2004) Standard cisplatin/infusional 5-flourouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinioma of the head and neck (LA-SCHHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). Abstract 5508, Proc Am Soc Clin OncolGoogle Scholar
  49. Vokes EE, Mick R, Lester EP et al (1991) Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution. J Clin Oncol 9:1376–1384PubMedGoogle Scholar
  50. Warde P, O’Sullivan B, Aslanidis J et al (2002) A phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 54:9–13PubMedCrossRefGoogle Scholar
  51. Wasserman TH, Brizel DM (2001a) The role of amifostine as a radioprotector. Oncology (Williston Park) 15:1349–1354; discussion 1357–1360PubMedGoogle Scholar
  52. Wasserman TH, Brizel DM (2001b) Has the outlook improved for amifostine as a clinical radioprotector. Radiother Oncol 60:334–336PubMedCrossRefGoogle Scholar
  53. Wasserman T, Mackowiak JI, Brizel DM et al (2000) Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. Int J Radiat Oncol Biol Phys 48:1035–1039PubMedCrossRefGoogle Scholar
  54. Wasserman TH, Brizel DM, Henke H et al (2005) Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and-neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 63:985–990PubMedCrossRefGoogle Scholar
  55. Wee J, Tan EH, Tai BC (2004) Phase III randomized trial of radiotherapy versus concurrent chemo-radiotherapy followed by adjuvant chemotherapy in patient with AJCC/UICC (1997). Stage 3 and 4 nasopharyngeal cancer of the endemic varitey. Proc Am Soc Clin Oncol 23:487Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • Deepak Khuntia
    • 1
  • Anne M. Traynor
    • 2
  • Paul M. Harari
    • 1
  • Jean Bourhis
    • 3
  1. 1.Department of Human OncologyUniversity of WisconsinMadisonUSA
  2. 2.Department of MedicineUniversity of WisconsinMadisonUSA
  3. 3.Head of Radiation Oncology DepartmentInstitute Gustave-RoussyVillejuif CedexFrance

Personalised recommendations